2024-07-14 10:23:41 ET
Summary
- Sana Biotechnology is a biotech company focused on developing engineered allogeneic cells for diseases with unmet clinical needs.
- Sana's most advanced product candidates leverage CRISPR technology to modify cells, with positive pre-clinical trial results and first in-human trials starting in late 2023.
- The company's pipeline includes oncology, autoimmune disease, and regenerative medicine product candidates, with a focus on UP421 and SC291 for T1DM and B-cell malignancies, respectively.
c
Thesis
Sana Biotechnology ( SANA ) is a biotech company in the early clinical-stage, focused on the development of engineered allogeneic cells (genetically-modified cells from healthy donors) for the treatment of diseases with unmet clinical needs.
Sana’s most advanced product candidates, including UP421, SC291 and SC262, leverage on Beam Therapeutics' (BEAM) CRISPR Cas12b nuclease gene editing technology, which enables the modification of specific markers. Sana has identified a series of gene modifications that facilitate allogeneic CAR-T cells to “hide” from the host immune system, while exhibiting a therapeutic function, e.g., killing altered B-cells (SC291 and SC262) causing cancer or autoimmune disorders, or in the case of UP421 to engraft and replace insulin producing cells without the need of immunosuppressants. Given the reduced capacity of Sana’s cells to trigger host immune response (hypo-immune), the company has named it, the “HIP platform”....
Read the full article on Seeking Alpha
For further details see:
Sana Biotechnology: Early-Stage Biotech With Promising Allogeneic CAR-T Pipeline